(Q31160116)

English

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 June 2017

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial (English)

1 reference

Europe PubMed Central

29 June 2017

1 reference

based on heuristic

inferred from title

Michael J. Boyer

object named as

M Boyer

6

0 references

object named as

T Mok

8

0 references

author name string

L Paz-Ares

1

1 reference

Europe PubMed Central

29 June 2017

E-H Tan

2

1 reference

Europe PubMed Central

29 June 2017

K O'Byrne

3

1 reference

Europe PubMed Central

29 June 2017

L Zhang

4

1 reference

Europe PubMed Central

29 June 2017

V Hirsh

5

1 reference

Europe PubMed Central

29 June 2017

J C-H Yang

7

1 reference

Europe PubMed Central

29 June 2017

K H Lee

9

1 reference

Europe PubMed Central

29 June 2017

S Lu

10

1 reference

Europe PubMed Central

29 June 2017

Y Shi

11

1 reference

Europe PubMed Central

29 June 2017

D H Lee

12

1 reference

Europe PubMed Central

29 June 2017

J Laskin

13

1 reference

Europe PubMed Central

29 June 2017

D-W Kim

14

1 reference

Europe PubMed Central

29 June 2017

S A Laurie

15

1 reference

Europe PubMed Central

29 June 2017

K Kölbeck

16

1 reference

Europe PubMed Central

29 June 2017

J Fan

17

1 reference

Europe PubMed Central

29 June 2017

N Dodd

18

1 reference

Europe PubMed Central

29 June 2017

A Märten

19

1 reference

Europe PubMed Central

29 June 2017

K Park

20

1 reference

Europe PubMed Central

29 June 2017

publication date

7 February 2017

1 reference

Europe PubMed Central

29 June 2017

Annals of Oncology

1 reference

Europe PubMed Central

29 June 2017

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391700

31 October 2018

Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391700

31 October 2018

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW611

21 January 2018

Identifiers

10.1093/ANNONC/MDW611

1 reference

Europe PubMed Central

29 June 2017

0 references

1 reference

Europe PubMed Central

29 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31160116&oldid=1646448605"